Previous 10 | Next 10 |
CHICAGO , Aug. 3, 2020 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo® (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. (...
Nothing about the Lexicon Pharmaceuticals ( LXRX ) story has been easy or conventional, and that includes the company's somewhat surprising decision to sell off its sole commercial product, Xermelo, and effectively return itself to a pre-revenue stage with a single asset in the clinic (LX921...
Taoping (NASDAQ: TAOP ) -23% . More news on: Taoping Inc., Precipio, Inc., Socket Mobile, Inc., Stocks on the move, , Read more ...
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2020 Earnings Conference Call July 30, 2020 08:00 ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief ...
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q2 2020 Earnings Call Jul 30, 2020 , 8:00 a.m. ET Operator Continue reading
FSD Pharma (NASDAQ: HUGE ) +130% . on decision to surrender health Canada licenses for subsidiary FV Pharma. More news on: FSD Pharma Inc., Kandi Technologies Group, Inc., Edesa Biotech, Inc., Stocks on the move, , Read more ...
Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract C...
THE WOODLANDS, Texas and DEERFIELD, Ill., July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, titl...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) : Q2 GAAP EPS of -$0.65 misses by $0.04 . More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
THE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020. “We achieved 21% growth in XERMELO net sales in the U.S. for the seco...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...